Brief: Basilea To In-License Novel Clinical Phase 3-Ready Oral Antibiotic

Basilea Pharmaceutica AG, Allschwil

14/08/2025 06:17

Aug 14 (Reuters) - Basilea Pharmaceutica AG Allschwil BSLN.S:

BASILEA ANNOUNCES IN-LICENSING OF A NOVEL CLINICAL PHASE 3-READY ORAL ANTIBIOTIC

BASILEA PHARMACEUTICA - VENATORX ELIGIBLE FOR UP TO USD 325 MILLION IN MILESTONE PAYMENTS

BASILEA PHARMACEUTICA - DEAL TO RESULT IN CHF 15 MILLION ADDITIONAL RESEARCH AND DEVELOPMENT EXPENSES IN 2025

BASILEA PHARMACEUTICA - EXCLUSIVE LICENSE AGREEMENT WITH VENATORX PHARMACEUTICALS, INC., TO ACQUIRE GLOBAL RIGHTS TO CEFTIBUTEN-LEDABORBACTAM ETZADROXIL

Source text: ID:nGNENZXXy

Further company coverage: BSLN.S

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))